Results 121 to 130 of about 7,987 (192)

Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China. [PDF]

Front Pharmacol
Fu Y, Li Z, Xia Q, Chen X, Xiang Z.
europepmc   +1 more source

Camrelizumab, Apatinib, and Radiotherapy in Locally Advanced, Unresectable Hepatocellular Carcinoma: A Phase II Study. [PDF]

Clin Cancer Res
Wang H, Wang K, Zheng X, Dong D, Zhu X, Sui X, Teng H, Xing B, Wang W.   +8 more
europepmc   +1 more source

Angiogenesis and apatinib

Journal of Cancer Research and Therapeutics, 2018
Yang, Ni, Xin, Ye
openaire   +2 more sources

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations: a cost-utility analysis. [PDF]

Front Pharmacol
Lang Y, Deng M, Yang J.
europepmc   +1 more source

Targeting Mitochondrial Dynamics in VEGFR-TKI Hypertension and Cardiotoxicity. [PDF]

Hypertension
Jankauskas SS, Kansakar U, Mone P, Pande S, Varzideh F, Santulli G.   +5 more
europepmc   +1 more source

Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis. [PDF]

Front Oncol
Li Y, Li Z, Shi X, Zuo H.
europepmc   +1 more source

Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. [PDF]

NPJ Precis Oncol
Zhao L, Gao C, Qiao X, Lou F, Zheng B, Fu M, Huang X, Xie X, Zhang W, Hong Y, Rong K, Shi H, Xiao L, Hu T.   +13 more
europepmc   +1 more source

An Evaluation of the Inhibitory Effect of Apatinib on Ilaprazole Metabolism: in vitro, in vivo and in silico Study. [PDF]

Drug Des Devel Ther
Li R, Jiang S, Chen Y, Wang P, Fu H, Wu J, Wu W.   +6 more
europepmc   +1 more source

Safety and Efficacy of Adebrelimab plus Apatinib Combined with Hepatic Artery Infusion Chemotherapy for the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study. [PDF]

ACS Pharmacol Transl Sci
Chen B, Zeng Y, Abdugheni K, Zeng L, Dai H, Tang K, Zhang G, Yang J, Huang Y, Lin R.   +9 more
europepmc   +1 more source

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. [PDF]

Front Oncol
Feng J, Qin X, Mo X.
europepmc   +1 more source